A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

NCT00479648 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

612

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: CSL412
BIOLOGICAL: Inactivated trivalent influenza vaccine

Sponsor

Seqirus